• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

DURECT Corp

NASDAQ:DRRX

$0.93 $0.07 (7.76%)

REAL-TIME: Last trade at

NASDAQ Changes Up Biotech Index Members & Weightings

NASDAQ Biotechnology Index - semi-annual changes

Durect files $50M mixed securities shelf

Durect reports Q1 EPS 35c, consensus (8c)

Pain Therapeutics issued four U.S. Patents for REMOXY

DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology

DURECT Corporation Invites You to Join its First Quarter 2012 Earnings Conference Call

Conus Partners reports 5.04% passive stake in Durect

Piper Jaffray's biotech and specialty pharma analysts hold a conference call

DURECT Receives Back U.S. and Canadian Product Rights to POSIDUR™

Durect reports Hospira returns rights to Posidur in U.S. and Canada

DURECT Receives Back U.S. and Canadian Product Rights to POSIDUR™

ThinkEquity Starts Durect Corp (DRRX) at Buy

Durect initiated with a Buy at ThinkEquity

Durect sees cash consumption of $12M in 2012

Durect reports Q4 EPS (2c), one estimate (8c)

Durect Corp (DRRX) Reports Q4 Loss of $0.02/Share

DURECT Corporation Announces Fourth Quarter and Year End 2011 Financial Results

DURECT Corporation Announces Fourth Quarter and Year End 2011 Financial Results

DURECT Corporation Invites You to Join Its Fourth Quarter 2011 Earnings Conference Call

DURECT to Participate in Upcoming Healthcare Conferences

DURECT to Present at the BIO CEO & Investor Conference

DURECT to Present at the BIO CEO & Investor Conference

Durect receives European product rights to Posidur

DURECT Announces Top-Line Data From BESST (POSIDUR® U.S. Pivotal Phase III Trial)

Durect shares nosedive on Phase III upset

Dendreon, Durect, Exide, Jazz, PriceSmart, Saba, Synta: U.S. Equity Movers

Durect to host conference call

DURECT Announces Top-line Data from BESST (POSIDUR U.S. Pivotal Phase III Trial)

Durect announces top-line data from BESST Posidur

Durect Corp (DRRX) Reports Top-line Data from BESST Phase III Trial Doesn't Meet Statistical Significance

DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial)

Durect trading halted, news pending

Making Cents in Penny Stocks

Durect Corp - Waiting For The BESST

Durect Corp. Reports Operating Results (10-Q)

DURECT Corporation to Participate in Upcoming Healthcare Conferences

Durect reports Q3 EPS (6c) vs. consensus (5c)

DURECT Corporation Announces Third Quarter 2011 Financial Results and Update of Programs

DURECT Corporation Invites You to Join its Third Quarter 2011 Earnings Conference Call

See More Articles...